Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol

Polymyxin B in Combination with Antimicrobials LackingIn VitroActivity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections

(2015) Maria Helena Rigatto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Improving predictions of the risk of resistance development against new and old antibiotics

(2015) D.I. Andersson   CLINICAL MICROBIOLOGY AND INFECTION

Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin

(2015) C.G. Giske   CLINICAL MICROBIOLOGY AND INFECTION

Strengths and limitations of industry vs. academic randomized controlled trials

(2015) P.-F. Laterre et al.   CLINICAL MICROBIOLOGY AND INFECTION

Revival of old antibiotics: structuring the re-development process to optimize usage

(2015) U. Theuretzbacher et al.   CLINICAL MICROBIOLOGY AND INFECTION

Optimization of dosing regimens and dosing in special populations

(2015) F.B. Sime et al.   CLINICAL MICROBIOLOGY AND INFECTION

Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective

(2015) A.E. Muller et al.   CLINICAL MICROBIOLOGY AND INFECTION

Infections caused by KPC-producingKlebsiella pneumoniae: differences in therapy and mortality in a multicentre study—authors' response

(2015) Mario Tumbarello et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Reviving old antibiotics

(2015) Ursula Theuretzbacher et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inter occasion variability in individual optimal design

(2015) Anders N. Kristoffersson et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus

(2015) Roger L Nation et al.   LANCET INFECTIOUS DISEASES

New Colistin Population Pharmacokinetic Data in Critically Ill Patients Suggesting an Alternative Loading Dose Rationale

(2014) N. Grégoire et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems

(2014) George L. Daikos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparison of colistin–carbapenem, colistin–sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections

(2014) A. Batirel et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival

(2014) Ilker Inanç Balkan et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Combination therapy for carbapenem-resistant Gram-negative bacteria

(2014) M. Paul et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Systematic Review and Meta-Analysis ofIn VitroSynergy of Polymyxins and Carbapenems

(2013) Oren Zusman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Patients enrolled in randomised clinical trials are not representative of critically ill patients in clinical practice: Observational study focus on tigecycline

(2013) Johannes B. Zimmermann et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae

(2013) K. Hussein et al.   JOURNAL OF HOSPITAL INFECTION

Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens

(2012) Zubair A. Qureshi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid Killing of Acinetobacter baumannii by Polymyxins Is Mediated by a Hydroxyl Radical Death Pathway

(2012) Timothy R. Sampson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill

(2012) Ami F. Mohamed et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy

(2012) M. Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries

(2011) H. Quan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients

(2011) S. M. Garonzik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Colistin pharmacokinetics: the fog is lifting

(2011) W. Couet et al.   CLINICAL MICROBIOLOGY AND INFECTION

Colistin: new lessons on an old antibiotic

(2011) D. Yahav et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clinical implications of β-lactam–aminoglycoside synergism: systematic review of randomised trials

(2011) Ronit Marcus et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital

(2010) C. A. DeRyke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Recommendations for Improving the Design, Conduct, and Analysis of Clinical Trials in Hospital‐Acquired Pneumonia and Ventilator‐Associated Pneumonia

(2010) John H. Powers   CLINICAL INFECTIOUS DISEASES

Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia

(2010) Brad Spellberg et al.   CLINICAL INFECTIOUS DISEASES

Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections

(2010) Chien-Yu Cheng et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Effectiveness and safety of colistin: prospective comparative cohort study

(2010) Mical Paul et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Risk factors for colistin-associated nephrotoxicity

(2010) Pinyo Rattanaumpawan et al.   JOURNAL OF INFECTION

Early Acute Kidney Injury Is a Risk Factor That Predicts Mortality in Patients Treated with Colistin

(2010) Hee ja Ko et al.   NEPHRON CLINICAL PRACTICE

Blocked Randomization with Randomly Selected Block Sizes

(2010) Jimmy Efird   International Journal of Environmental Research and Public Health

Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria

(2009) D. Plachouras et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center

(2009) Joshua D. Hartzell et al.   CLINICAL INFECTIOUS DISEASES

Clinical characteristics and risk factors of colistin-induced nephrotoxicity

(2009) Jieun Kim et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care setting

(2008) Teresa C. Horan et al.   AMERICAN JOURNAL OF INFECTION CONTROL

Trends in the methodological quality of published randomized controlled trials on antibacterial agents

(2008) Matthew E. Falagas et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic and Pharmacodynamic Properties of Meropenem

(2008) David P. Nicolau   CLINICAL INFECTIOUS DISEASES

Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria

(2008) Vicente Pintado et al.   JOURNAL OF INFECTION